Paper33859752
Turning cold tumors into hot tumors by improving T-cell infiltration.
Liu YT and 1 other. Theranostics, 2021. Cited by 680 papers, by iCite.
Cite this record
ConductScience Library. Turning cold tumors into hot tumors by improving T-cell infiltration. Papers, record 33859752. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/33859752
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Neoplasms | Major topic |
| T-Lymphocytes | Major topic |
| Animals | |
| Antigens, Neoplasm | |
| Humans | |
| Immunotherapy | |
| Nanomedicine |
Source PubMed
References176
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 32699309 | Clinical development and potential of photothermal and photodynamic therapies for cancer. | Nat Rev Clin Oncol | 2020 | https://conductscience.org/library/papers/32699309 | PubMed |
| 2 | 28187290 | Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. | Cell | 2017 | https://conductscience.org/library/papers/28187290 | PubMed |
| 3 | 26411680 | Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner. | Cell Rep | 2015 | https://conductscience.org/library/papers/26411680 | PubMed |
| 4 | 28486109 | Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy. | Cancer Cell | 2017 | https://conductscience.org/library/papers/28486109 | PubMed |
| 5 | 29443960 | TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. | Nature | 2018 | https://conductscience.org/library/papers/29443960 | PubMed |
| 6 | 32117585 | PT-112 induces immunogenic cell death and synergizes with immune checkpoint blockers in mouse tumor models. | Oncoimmunology | 2020 | https://conductscience.org/library/papers/32117585 | PubMed |
| 7 | 22592077 | The immunosuppressive factors IL-10, TGF-β, and VEGF do not affect the antigen-presenting function of CD40-activated B cells. | J Exp Clin Cancer Res | 2012 | https://conductscience.org/library/papers/22592077 | PubMed |
| 8 | 28231431 | Enhancing Adoptive Cell Therapy of Cancer through Targeted Delivery of Small-Molecule Immunomodulators to Internalizing or Noninternalizing Receptors. | ACS Nano | 2017 | https://conductscience.org/library/papers/28231431 | PubMed |
| 9 | 32760014 | Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. | Nat Rev Clin Oncol | 2020 | https://conductscience.org/library/papers/32760014 | PubMed |
| 10 | 30914826 | Navigating metabolic pathways to enhance antitumour immunity and immunotherapy. | Nat Rev Clin Oncol | 2019 | https://conductscience.org/library/papers/30914826 | PubMed |
| 11 | 31548600 | The emerging role of epigenetic therapeutics in immuno-oncology. | Nat Rev Clin Oncol | 2020 | https://conductscience.org/library/papers/31548600 | PubMed |
| 12 | 29431745 | DKK2 imparts tumor immunity evasion through β-catenin-independent suppression of cytotoxic immune-cell activation. | Nat Med | 2018 | https://conductscience.org/library/papers/29431745 | PubMed |
| 13 | 26321679 | Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression. | Cell | 2015 | https://conductscience.org/library/papers/26321679 | PubMed |
| 14 | 22224781 | Regulatory T cells: mechanisms of differentiation and function. | Annu Rev Immunol | 2012 | https://conductscience.org/library/papers/22224781 | PubMed |
| 15 | 30849371 | VEGF in Signaling and Disease: Beyond Discovery and Development. | Cell | 2019 | https://conductscience.org/library/papers/30849371 | PubMed |
| 16 | 27718784 | Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. | N Engl J Med | 2016 | https://conductscience.org/library/papers/27718784 | PubMed |
| 17 | 26014293 | Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. | J Clin Oncol | 2015 | https://conductscience.org/library/papers/26014293 | PubMed |
| 18 | 31690840 | The gasdermins, a protein family executing cell death and inflammation. | Nat Rev Immunol | 2020 | https://conductscience.org/library/papers/31690840 | PubMed |
| 19 | 29025772 | Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer. | Cancer Discov | 2017 | https://conductscience.org/library/papers/29025772 | PubMed |
| 20 | 29120755 | Migrating into the Tumor: a Roadmap for T Cells. | Trends Cancer | 2017 | https://conductscience.org/library/papers/29120755 | PubMed |
Cited by509
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 680 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42979366 | Biomimetic tumor microenvironment-responsive prodrug amplifies photoimmunotherapy via TLR2 agonist. | Acta Pharm Sin B | 2026 | https://conductscience.org/library/papers/42979366 | PubMed |
| 42973806 | Ultrasound-responsive nanoplatforms for cancer immunotherapy: engineering spatiotemporal immune activation in the tumor microenvironment. | Front Immunol | 2026 | https://conductscience.org/library/papers/42973806 | PubMed |
| 42920907 | Molecular and immune-mediated resistance to antibody-drug conjugates in breast cancer. | Front Immunol | 2026 | https://conductscience.org/library/papers/42920907 | PubMed |
| 42909908 | Targeting NOTCH-immune crosstalk in gliomas: from mechanisms to therapeutics. | Front Oncol | 2026 | https://conductscience.org/library/papers/42909908 | PubMed |
| 42877086 | Biomaterial-driven remove-remodel-repair (3R) strategy for full-cycle gastric cancer management: bibliometric mapping, preclinical evidence, and a translational roadmap. | Nanoscale Adv | 2026 | https://conductscience.org/library/papers/42877086 | PubMed |
| 42876375 | Clinicopathological Features of DLL3 Expression and T-Cell Infiltration in LCNEC: Insights From Pathology and Clinical Response to Tarlatamab. | Thorac Cancer | 2026 | https://conductscience.org/library/papers/42876375 | PubMed |
| 42795401 | The Relationship Between Immunogenic Cell Death and Cellular Senescence in Cancer Immunotherapy. | Life (Basel) | 2026 | https://conductscience.org/library/papers/42795401 | PubMed |
| 42753002 | Cancer-Testis Antigens in Immuno Oncology Mechanisms Therapeutic Strategies and Clinical Perspectives. | J Immunol Res | 2026 | https://conductscience.org/library/papers/42753002 | PubMed |
| 42699686 | Targeted PD-L1 degradation with an injectable hydrogel reverses chemotherapy-induced compensatory immunosuppression and enhances antitumor immunity. | Mater Today Bio | 2026 | https://conductscience.org/library/papers/42699686 | PubMed |
| 42695424 | Dendritic cell‑based vaccines for colorectal cancer: Mechanisms, clinical progress and future directions (Review). | Int J Oncol | 2026 | https://conductscience.org/library/papers/42695424 | PubMed |
| 42614350 | A tissue microenvironment analogous to certain tumor microenvironments facilitates HIV persistence. | Front Immunol | 2026 | https://conductscience.org/library/papers/42614350 | PubMed |
| 42608511 | Cold and hot tumors: immunological determinants, cancer-immunity cycle dysregulation, and nanotechnology-driven therapeutic approaches. | Mol Biomed | 2026 | https://conductscience.org/library/papers/42608511 | PubMed |
| 42597511 | Development and Validation of an HPLC-MS/MS Method for Determining BMS-1166, GB-1107, and Enzalutamide in Rat Plasma and Its Application to Pharmacokinetic Studies. | Drug Des Devel Ther | 2026 | https://conductscience.org/library/papers/42597511 | PubMed |
| 42596654 | cGAS-STING pathway activation drives the cold-to-hot tumor transition and sensitizes immunotherapy. | Cancer Biol Med | 2026 | https://conductscience.org/library/papers/42596654 | PubMed |
| 42564263 | Tumor organoid-immune cell co-culture systems for precision oncology. | Front Cell Dev Biol | 2026 | https://conductscience.org/library/papers/42564263 | PubMed |
| 42536164 | NKR+CD8+ T cells and iNKT cells protect mice from AOM/DSS-induced colorectal cancer under conditions of IFNγ-mediated hyperinflammation. | Inflamm Res | 2026 | https://conductscience.org/library/papers/42536164 | PubMed |
| 42521766 | Symmetric cancer spheroid-fibroblast organization revealed in 3D by high-throughput microscopy. | Commun Biol | 2026 | https://conductscience.org/library/papers/42521766 | PubMed |
| 42512390 | Prognostic Value of Morphological Characteristics and Immune Microenvironment in High-Grade Serous Cancer (HGSC). | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42512390 | PubMed |
| 42467537 | PANoptosis and Immune Remodeling in the Tumor Microenvironment. | FASEB J | 2026 | https://conductscience.org/library/papers/42467537 | PubMed |
| 42459668 | Immune checkpoint inhibitors in dMMR-MSI-H colorectal cancer: rationale, progress and prospects. | Front Immunol | 2026 | https://conductscience.org/library/papers/42459668 | PubMed |
Genes34
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/33859752
GET https://conductscience.org/api/papers/v1/33859752/references?page=2